GELS (GELS) Stock Price & Analysis
GELS (GELS) fell 24.87% to USD 0.68 as of September 9, 2026 at 10:10 UTC, according to Nexqual real-time market data.
GELS last closed at USD 0.9; the session ranged USD 0.63–0.83 on volume of 528,631 shares. Market capitalization is $7.24M, with a 52-week range of USD 0.39–2.01 (NCM). Source: Nexqual, September 9, 2026 at 10:10 UTC.
Key Statistics (as of September 9, 2026 at 10:10 UTC)
| Price | USD 0.68 |
|---|---|
| Change | ▼ 24.87% (down) |
| Previous Close | USD 0.9 |
| Open | USD 0.83 |
| Day Range | USD 0.63 – 0.83 |
| 52-Week Range | USD 0.39 – 2.01 |
| Volume | 528,631 shares |
| Market Cap | $7.24M |
| Exchange | NCM |
Technical Analysis (GELS)
Nexqual's technical model rates GELS "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 10:10 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.31 (neutral) |
| vs SMA50 | Above (USD 0.6) |
| MACD | 0.04 (positive) |
Analyst Ratings (GELS)
Wall Street analysts rate GELS "None", per Nexqual as of September 9, 2026 at 10:10 UTC.
| Consensus Rating | None |
|---|
Earnings (GELS)
Source: Nexqual, September 9, 2026 at 10:10 UTC.
Financials & Fundamentals (GELS)
| Total Revenue | $471,799 |
|---|---|
| Revenue Growth (YoY) | +48.90% |
| Gross Margin | +75.54% |
| Operating Margin | -1985.28% |
| Profit Margin | +0.00% |
| ROE | -42.93% |
| Debt / Equity | 36.01 |
| Current Ratio | 0.09 |
| Total Cash | $9,349 |
| Total Debt | $5.11M |
| Free Cash Flow | $-4.75M |
Source: Nexqual, September 9, 2026 at 10:10 UTC.
Financial Health Score (GELS)
Nexqual rates GELS's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 10:10 UTC.
| Growth | Strong — Revenue +49% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $9K cash vs $5M debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -43%, ROA -17.6% |
Ownership (GELS)
| Insider Ownership | +47.53% |
|---|---|
| Institutional Ownership | +1.03% |
| Shares Outstanding | 10.71M |
| Float | 5.15M |
| Short % of Float | +0.18% |
Source: Nexqual, September 9, 2026 at 10:10 UTC.
Leadership (GELS)
GELS is led by Nathan Jacob Givoni (age 41), Co-Founder, CEO & Executive Director, per Nexqual as of September 9, 2026 at 10:10 UTC.
| Co-Founder, CEO & Executive Director | Nathan Jacob Givoni (age 41) |
|---|---|
| Co-Founder & Non-Executive Chairman | Simon Hayden Szewach (age 45) |
| Chief Financial Officer | Thuy-Linh Gigler (age 45) |
| Chief Scientific Officer | Paul M. Wynne (age 62) |
| President of U.S. Operations | Adam Bendell |
Major Backers & Investors (GELS)
Notable institutional backers of GELS include Two Sigma Securities, LLC, Jane Street Group, LLC, Wedbush Securities Inc, according to Nexqual as of September 9, 2026 at 10:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Two Sigma Securities, LLC | 0.31% |
| Jane Street Group, LLC | 0.28% |
| Wedbush Securities Inc | 0.19% |
| Morgan Stanley | 0.14% |
| Citadel | 0.11% |
Source: Nexqual, September 9, 2026 at 10:10 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AZI | Autozi Internet Technology (Glo | USD 1.28 | ▲ 0.79% |
| PLRZ | Polyrizon Ltd. | USD 11.15 | ▼ 11.23% |
| IVF | INVO Fertility, Inc. | USD 0.98 | ▼ 0.1% |
| KIDZ | KIDZ AI Inc. | USD 3.69 | ▼ 7.75% |
| ATPC | Agape ATP Corporation | USD 2.31 | ▼ 3.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:10 UTC. This page is informational and not investment advice.